ADMA AI Stock Analysis

AlphaCrew

ADMA Biologics, Inc. (ADMA)

AI Verdict

Confidence 86%

ADMAADMA Biologics, Inc.

AlphaCrew AI

BUY

Overall

Summary

ADMA Biologics presents a compelling investment opportunity driven by strong fundamental improvements, solid profitability, and a niche market position in plasma-derived biologics. While technical signals suggest short-term caution due to a topping phase, the medium and long-term outlooks remain positive supported by steady revenue growth, margin expansion, and regulatory tailwinds. Valuation is fair relative to peers, and sentiment is moderately positive with analyst buy consensus. Risks from plasma supply and regulatory challenges exist but are balanced by robust liquidity and manageable leverage.

By Timeframe

Hover for details

HOLD

Short

BUY

Medium

BUY

Long

Agent Signals

14

Fund

Tech

Val

Sent

Risk

Analyzed Oct 28, 2026, 2:52 PM UTC

Fundamentals

Essentia

Fundamental Analysis

BULLISH

ADMA Biologics has demonstrated a solid financial turnaround with consistent revenue growth and improving profitability since fiscal 2023's losses. The company has leveraged its biologics portfolio well to expand gross margins to around 69% in the latest reported quarter, reflecting operational efficiency and product demand. While earnings remain somewhat volatile quarter-to-quarter, overall bottom-line performance is strengthening with resilient cash flow generation potential.

Overview

ADMA Biologics specializes in developing and commercializing specialty plasma-derived biologics primarily focused on immunoglobulin-based therapies targeting immune deficiencies and infectious diseases. The company operates in the biotechnology sector emphasizing plasma protein therapies with growing FDA-approved product offerings.

Market Position

ADMA holds a niche position in the plasma biologics market, competing with larger pharmaceutical firms through its focus on specialized immunobiologics. Its market presence is bolstered by regulatory approvals and a targeted product pipeline addressing unmet patient needs in immune disorders.

Competitive Advantages

Key competitive advantages include proprietary plasma processing technologies, FDA-approved proprietary products, a focused therapeutic niche with high barriers to entry, long-term supply agreements, and expertise in plasma biologics manufacturing and distribution. These create meaningful moats in a highly specialized biotech segment.

✓ Strong revenue and earnings growth trajectory with improving margins✓ Niche biologics market position with regulatory approvals and product moat✓ Solid operational leverage and scalable business model⚠ Modest recent revenue and EPS estimate misses indicate potential near-term volatility⚠ Dependence on plasma supply and regulatory environment introduces risk⚠ Competition from larger pharmaceutical and biotech firms could pressure pricing

Financial Highlights

Growth Metrics

Profitability Metrics

Technical Analysis

Candela

Technical Analysis

NEUTRAL

ADMA Biologics is currently in a topping phase with price action showing signs of distribution. The stock remains in a bullish uptrend above its 50 and 150 SMAs but is facing resistance around the 200 SMA, with momentum neutral and caution advised near critical moving averages. Chart patterns suggest potential volatility ahead, making it important to watch key support and resistance levels closely.

Key Insights

The stock is trading above the 50-day and 150-day SMAs but slightly below the 200-day SMA, indicating mixed moving average signals with a recent death cross. The ADX reading above 25 confirms a strong trend, albeit in the topping phase, with RSI in a neutral zone, showing balanced momentum. Volume patterns do not strongly confirm breakouts, suggesting possible consolidation or distribution.

Trend Analysis

Primary trend is bullish as price is above both 50 and 150 SMA, but the crossing below the 200 SMA and stage 3 labeling indicates a potential end to the uptrend. The secondary trend shows volatility with no clear direction, indicating possible sideways movement or distribution.

Momentum

Momentum is currently neutral to slightly fading as RSI hovers around 65 and is not in overbought territory. The ADX signals a strong trend, but caution is warranted due to the topping phase and mixed moving average signals.

Price Targets

Upside target near $12.50 if the stock breaks decisively above the 200 SMA and consolidates. Downside targets include $9.50 (50 SMA) and $9.00 if the price breaks below the 150 SMA support level.

Entry Zone

Consider entering near $9.50-$10.00 zone where the 50 and 150 SMAs offer support, with stops tightened if price falls below $9.00 or the 150 SMA breaks down.

Earnings

Essentia

Fundamental Analysis

BULLISH

ADMA Biologics has demonstrated a solid financial turnaround with consistent revenue growth and improving profitability since fiscal 2023's losses. The company has leveraged its biologics portfolio well to expand gross margins to around 69% in the latest reported quarter, reflecting operational efficiency and product demand. While earnings remain somewhat volatile quarter-to-quarter, overall bottom-line performance is strengthening with resilient cash flow generation potential.

Valuation

Valorem

Valuation Analysis

FAIRLY VALUED

ADMA Biologics currently presents a valuation profile that suggests it is trading with a moderate premium relative to historical norms but remains attractive compared to its biotechnology peers. The company's strong profitability metrics combined with solid financial health underpin its valuation, while recent analyst ratings indicate a moderate buy consensus. Growth prospects appear steady, supporting a valuation that reflects both its earnings potential and sector positioning.

Overview

Collectively, the valuation metrics show ADMA has maintained consistent profitability with improving margins and reasonable earnings growth, supported by a healthy balance sheet and strong liquidity. Its current multiples reflect a shift from historically elevated valuations to more moderate levels in the latest quarters.

Sector Comparison

Relative to the biotechnology sector, ADMA's valuation multiples such as P/E and EV/EBITDA are somewhat compressed, indicating a potential undervaluation against peer averages that typically command higher multiples due to growth expectations. Its profitability and returns metrics outpace many peers, suggesting strong operational efficiency.

Standout Metrics

Notably, ADMA's gross and operating margins are robust for the biotechnology industry, with exceptional current and quick ratios signaling excellent liquidity. Its historical peak valuations on price-to-sales and EV multiples have moderated to more reasonable levels recently, indicating improved value for investors.

Sentiment & Analyst Ratings

Pulse

Sentiment Analysis

MIXED

Market sentiment for ADMA Biologics is moderately positive, supported by strong analyst buy ratings and confidence in ASCENIV's growth potential in the underserved plasma-derived therapy market. News coverage highlights solid financial results and cautious optimism amid competitive pressures, while social media sentiment is mixed but generally leans toward cautious optimism given recent revenue trends and regulatory progress.

Key Themes

Financial results showing ASCENIV revenue growth and steady cash flow, evolving competitive dynamics in plasma-derived therapies, and regulatory advancements including expanded IVIG label indications. Also discussed are cautious revenue guidance revisions and accelerated share repurchases.

Recent Developments

ADMA reported solid Q2 2026 results with promising ASCENIV product penetration and steady revenue growth despite competitive market pressures; long-term guidance withdrawn reflecting market evolution. FDA expanded IVIG label to pediatric patients.

Media Coverage

Media coverage has been steady with generally positive tone on quarterly earnings updates and business execution, though some caution noted on competitive landscape and past revenue shortfalls. Coverage is modest in volume but focused on financial and regulatory updates.

Analyst Sentiment

Analysts maintain a favorable view overall with a majority rating the stock as buy or strong buy, emphasizing confidence in ASCENIV growth and ADMA's financial health while acknowledging market competition and product mix challenges.

Risk Assessment

Sentinel

Risk Assessment

MODERATE

ADMA Biologics demonstrates a solid financial position with robust liquidity and moderate leverage, supported by improving utilization and revenue growth in its core IVIG products. While competitive pressures and market dynamics pose risks, the company is benefiting from recent regulatory approvals that expand its addressable market, maintaining a favorable outlook with effective debt management.

Key Risk Factors

Competitive pressures in the immunoglobulin and plasma-derived therapies market, regulatory and clinical trial uncertainties, risk of adverse events such as thrombosis in treatment products, and reliance on continued product demand expansion.

Risk vs Sector

ADMA Biologics presents somewhat lower financial risk than many biotechnology peers due to its conservative debt levels and strong liquidity, but it faces typical sector risks related to regulatory hurdles and product competition.

Risk Summary

Although ADMA operates in a high-risk biotech sector, its strong balance sheet and careful debt management reduce financial risk. The main vulnerabilities stem from competitive dynamics and regulatory dependencies typical in biotech, making it moderately risky for investors who seek growth tempered by solid financial discipline.

Frequently Asked Questions about ADMA

AI Answers: Common Questions About ADMA

Get AI-powered answers to the questions investors ask most about ADMA Biologics, Inc.

Yes, ADMA is a good buy for medium to long-term investors given its strong revenue growth from $258M in 2023 to $510M in 2025, improving gross margins near 69%, and a reasonable P/E of 15.81 supporting stable earnings growth.

Not currently. While short-term technical signals suggest caution, fundamentals and valuation support holding or buying. Consider selling only if price breaks below key support levels near $9.00 or if regulatory setbacks occur.

Key risks include regulatory and clinical trial uncertainties, plasma supply shortages, and competitive pressures from larger firms. These could impact product approvals, pricing, and sales growth.

Upside price target is near $12.50 if the stock breaks above the 200 SMA resistance. Downside support levels are $9.50 and $9.00 based on 50 and 150 SMAs.

ADMA is fairly valued with a trailing P/E of 15.81, EV/EBITDA and price-to-sales ratios normalized from historical highs, reflecting sustainable profitability and moderate growth expectations.

Fundamentals are strong with revenue growth from $258M to $510M over two years, gross margins improving from 34% to nearly 69%, EBITDA margins above 44%, and consistent net income margins around 30%.

Technically, the stock is in a topping phase with neutral momentum and resistance near $11.02 (200 SMA). Volume does not confirm breakouts, suggesting possible consolidation or volatility in the short term.

Key catalysts include expanded FDA approvals for ASCENIV and IVIG, pipeline product launches, and quarterly earnings reports showing continued revenue and margin growth.

Want a Personalized Answer?

Get AI-powered insights tailored to your risk tolerance and investment goals.

More AI Stock Analyses

AAPL NVDA TSLA MSFT AMZN GOOGL View All

ADMA AI Stock Analysis – Buy, Hold, or Avoid?

ADMA Biologics, Inc. (ADMA)

Fundamentals

Financial Highlights

Growth Metrics

Profitability Metrics

Technical Analysis

Earnings

Valuation

Sentiment & Analyst Ratings

Risk Assessment

Frequently Asked Questions about ADMA

AI Answers: Common Questions About ADMA

Is ADMA stock a good buy right now?AI

Should I sell ADMA stock now?AI

What are the biggest risks for ADMA stock?AI

What is the ADMA price target or forecast for the next 12 months?AI

Is ADMA overvalued or undervalued right now?AI

Is ADMA fundamentally strong?AI

What does technical analysis say about ADMA support and resistance?AI

What are the key catalysts to watch for ADMA?AI

Want a Personalized Answer?

More AI Stock Analyses